

## SEARCH REQUEST FORM


Scientific and Technical Information Center

Requester's Full Name: S. Kumar Examiner #: 695941 Date: 5/17/03Art Unit: 1621 Phone Number 301 272-0640 Serial Number: 101023933Mail Box and Bldg/Room Location: REM 5261 Results Format Preferred (circle): PAPER DISK E-MAIL  
5C18 M/EI**If more than one search is submitted, please prioritize searches in order of need.**

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: New Oxybenzamide Derivatives useful for inhibiting factor XaInventors (please provide full names): Marc Nagore et alEarliest Priority Filing Date: 12/23/2000

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



$\text{A}^0$  is monocyclic or bicyclic aryl or heteroaryl

$\text{Q}$  &  $\text{Q}'$  are bond,  $(\text{CH}_2)_n - \text{O} - (\text{CH}_2)_m$ , or R, w.e.

X bond, heteroaryl; alkylene w.e.


W aryl, heteroaryl

R, H,  $\text{NO}_2$ , etc. etc.

U & G are  $(\text{CH}_2)_n$ , etc.

M H, alkyl etc.

V bond, alkylene



Species:

See claims  
especially  
claim 10

## STAFF USE ONLY

Searcher: Beverly C 2528

## Type of Search

## Vendors and cost where applicable

NA Sequence (#) \_\_\_\_\_ STN \_\_\_\_\_

AA Sequence (#) \_\_\_\_\_ Dialog \_\_\_\_\_

Structure (#) \_\_\_\_\_ Questel/Orbit \_\_\_\_\_

Bibliographic \_\_\_\_\_ Dr. Link \_\_\_\_\_

Litigation \_\_\_\_\_ Lexis/Nexis \_\_\_\_\_

Fulltext \_\_\_\_\_ Sequence Systems \_\_\_\_\_

Patent Family \_\_\_\_\_ WWW/Internet \_\_\_\_\_

Other \_\_\_\_\_ Other (specify) \_\_\_\_\_


Kumar, S.  
10/023933

10/023933

(FILE 'REGISTRY' ENTERED AT 11:10:37 ON 19 MAY 2004)

L3

STR



## Species

```
VAR G1=C/N  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:  
RSPEC I  
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE  
L5 20 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 27 ITERATIONS 20 ANSWERS  
SEARCH TIME: 00.00.01

L6 (FILE 'HCAPLUS' ENTERED AT 11:30:59 ON 19 MAY 2004) L5

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS ON SIN  
ACCESSION NUMBER: 2002:486185 HCAPLUS  
DOCUMENT NUMBER: 137:63256  
TITLE: Preparation of heterocyclyl benzamides as  
inhibitors of factor Xa and factor VIIa.  
INVENTOR(S): Nazare, Marc; Will, David William; Peyman,  
Anuschirwan; Matter, Hans; Zoller, Gerhard;  
Gerlach, Uwe  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: Eur. Pat. Appl., 101 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

Searcher : Shears 571-272-2528

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1217000	A1	20020626	EP 2000-128477	20001223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
WO 2002051831	A1	20020704	WO 2001-EP14842	20011215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1349847	A1	20031008	EP 2001-272016	20011215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300306	A	20031015	EE 2003-306	20011215
BR 2001016473	A	20040113	BR 2001-16473	20011215
US 2002198195	A1	20021226	US 2001-23933	20011221
NO 2003002820	A	20030821	NO 2003-2820	20030619
PRIORITY APPLN. INFO.:			EP 2000-128477	A 20001223
			WO 2001-EP14842	W 20011215

## OTHER SOURCE(S): MARPAT 137:63256

AB RQXQ1WUVGM [R = (substituted) aryl, heteroaryl; Q, Q1 = bond, CO, O, S, imino, carbonylimino, SO, SO<sub>2</sub>, (substituted) alkylene, etc.; X = bond, heteroaryl, (substituted) alkylene, heteroalkylene; W = (substituted) aryl, heteroaryl, mono-, polycyclic group; U, G = bond, (CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m</sub>O(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>m</sub>CO(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>m</sub>S(CH<sub>2</sub>)<sub>n</sub>, etc.; m, n = 0-6; V = bond, (substituted) alkylene, aryl, heteroaryl, cyclic group; M = H, alkyl, (substituted) alkylaminocarbonyl, aryl, heteroaryl, cyclic group; with provisos], were prepared Thus, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxybenzoic acid, N-NEM, 1-(pyridin-4-ylmethyl)piperazine, and TOTU were stirred in DMF to give [3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxyphenyl](4-pyridin-4-ylmethypiperazin-1-yl)methanone. The latter inhibited factor Xa with Ki = 0.600 μM.

IT 438570-10-6P 438570-12-8P 438570-14-0P  
 438570-24-2P 438570-61-7P 438570-63-9P  
 438570-68-4P 438570-69-5P 438570-79-7P  
 438570-80-0P 438570-81-1P 438570-82-2P  
 438570-83-3P 438570-85-5P 438570-86-6P  
 438570-88-8P 438570-90-2P 438570-91-3P  
 438570-94-6P 438571-00-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocycl benzamides as inhibitors of factor Xa and factor VIIa)

RN 438570-10-6 HCPLUS


CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4,5-dimethoxy-N-[(1-(4-pyridinyl)-4-piperidinyl)methyl]-(9CI) (CA INDEX NAME)

10/023933




RN 438570-12-8 HCPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-N-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 438570-14-0 HCPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-ethoxy-N-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 438570-24-2 HCPLUS

CN Benzamide, 4-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-5-methoxy-N-[(1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 438570-61-7 HCPLUS


Searcher : Shears 571-272-2528

10/023933

CN Benzamide, N-([1,4'-bipiperidin]-4-ylmethyl)-3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy- (9CI) (CA INDEX NAME)




CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-[[1-(2-methyl-4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438570-68-4 HCPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-[[1-(1-oxido-4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-69-5 HCPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-79-7 HCPLUS


Searcher :

Shears

571-272-2528


10/023933

CN Benzamide, 4-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438570-80-0 HCPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438570-81-1 HCPLUS

CN Benzamide, 4-amino-3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-82-2 HCPLUS


CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-fluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-83-3 HCPLUS


10/023933

CN Benzamide, 2-chloro-5-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438570-85-5 HCPLUS

CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-5-methoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438570-86-6 HCPLUS

CN Benzamide, 5-[2-(2,4-dichlorophenyl)ethoxy]-2-nitro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438570-88-8 HCPLUS

CN Benzamide, 4-bromo-3-[2-(2,4-dichlorophenyl)ethoxy]-5-hydroxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




10/023933


RN 438570-90-2 HCAPLUS  
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 438570-91-3 HCAPLUS  
CN Benzamide, 4-cyano-3-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 438570-94-6 HCAPLUS  
CN Benzamide, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-(methylthio)-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 438571-00-7 HCAPLUS  
CN 1,3-Benzenedicarboxamide, 5-[2-(2,4-dichlorophenyl)ethoxy]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Searcher :

Shears

571-272-2528

10/023933



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE  
IN THE RE FORMAT

L7 FILE 'CAOLD' ENTERED AT 11:32:34 ON 19 MAY 2004  
0 S L5

L8 FILE 'USPATFULL' ENTERED AT 11:32:42 ON 19 MAY 2004  
1 S L5

L8 ANSWER 1 OF 1 USPATFULL on STN  
ACCESSION NUMBER: 2002:344465 USPATFULL  
TITLE: New oxybenzamide derivatives useful for  
inhibiting factor Xa or VIIa  
INVENTOR(S): Nazare, Marc, Eppstein, GERMANY, FEDERAL REPUBLIC  
OF  
Will, David William, Kriftel, GERMANY, FEDERAL  
REPUBLIC OF  
Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL  
REPUBLIC OF  
Matter, Hans, Langenselbold, GERMANY, FEDERAL  
REPUBLIC OF  
Zoller, Gerhard, Schoneck, GERMANY, FEDERAL  
REPUBLIC OF  
Gerlach, Uwe, Hattersheim, GERMANY, FEDERAL  
REPUBLIC OF


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198195	A1	20021226
APPLICATION INFO.:	US 2001-23933	A1	20011221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-128477	20001223
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7503	

Searcher : Shears 571-272-2528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds comprising the following formula:




These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'MARPAT' ENTERED AT 11:33:02 ON 19 MAY 2004)

L9 STR



VAR G1=C/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

10/023933

ATTRIBUTES SPECIFIED AT SEARCH-TIME:  
ECLEVEL IS LIM ON ALL NODES  
ALL RING(S) ARE ISOLATED

L11 1 SEA FILE=MARPAT SSS FUL L9 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 2288 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.12

L11 ANSWER 1 OF 1 MARPAT COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 137:63256 MARPAT  
TITLE: Preparation of heterocycl benzamides as  
inhibitors of factor Xa and factor VIIa.  
INVENTOR(S): Nazare, Marc; Will, David William; Peyman,  
Anuschirwan; Matter, Hans; Zoller, Gerhard;  
Gerlach, Uwe  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: Eur. Pat. Appl., 101 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1217000	A1	20020626	EP 2000-128477	20001223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002051831	A1	20020704	WO 2001-EP14842	20011215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1349847	A1	20031008	EP 2001-272016	20011215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300306	A	20031015	EE 2003-306	20011215
BR 2001016473	A	20040113	BR 2001-16473	20011215
US 2002198195	A1	20021226	US 2001-23933	20011221
NO 2003002820	A	20030821	NO 2003-2820	20030619
PRIORITY APPLN. INFO.:			EP 2000-128477	20001223
			WO 2001-EP14842	20011215
AB RQXQ1WUVGM [R = (substituted) aryl, heteroaryl; Q, Q1 = bond, CO, O, S, imino, carbonylimino, SO, SO <sub>2</sub> , (substituted) alkylene, etc.; X = bond, heteroaryl, (substituted) alkylene, heteroalkylene; W = (substituted) aryl, heteroaryl, mono-, polycyclic group; U, G = bond, (CH <sub>2</sub> ) <sub>m</sub> , (CH <sub>2</sub> ) <sub>m</sub> O(CH <sub>2</sub> ) <sub>n</sub> , (CH <sub>2</sub> ) <sub>m</sub> CO(CH <sub>2</sub> ) <sub>n</sub> , (CH <sub>2</sub> ) <sub>m</sub> S(CH <sub>2</sub> ) <sub>n</sub> , etc.; m, n = 0-6; V = bond, (substituted) alkylene, aryl, heteroaryl, cyclic				

group; M = H, alkyl, (substituted) alkylaminocarbonyl, aryl, heteroaryl, cyclic group; with provisos], were prepared. Thus, 3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxybenzoic acid, N-NEM, 1-(pyridin-4-ylmethyl)piperazine, and TOTU were stirred in DMF to give [3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxyphenyl](4-pyridin-4-ylmethypiperazin-1-yl)methanone. The latter inhibited factor Xa with  $K_i = 0.600 \mu\text{M}$ .

- IC ICM C07D401-00  
 ICS C07D213-30; C07D333-16; C07D333-58; A61K031-38; A61K031-435  
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 ST heterocycl benzamide blood coagulation factor inhibitor;  
 cardiovascular agent heterocycl benzamide prep  
 IT Respiratory distress syndrome  
 (adult, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Heart, disease  
 (angina pectoris, treatment of unstable angina; preparation of  
 heterocycl benzamides as inhibitors of factor Xa and factor  
 VIIa)  
 IT Artery, disease  
 (coronary, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Heart, disease  
 (infarction, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Brain, disease  
 (ischemia, transient, treatment; preparation of heterocycl  
 benzamides as inhibitors of factor Xa and factor VIIa)  
 IT Anti-inflammatory agents  
 Anticoagulants  
 Antitumor agents  
 Antiviral agents  
 Cardiovascular agents  
 (preparation of heterocycl benzamides as inhibitors of factor Xa and  
 factor VIIa)  
 IT Artery, disease  
 (restenosis, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Shock (circulatory collapse)  
 (septic, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Brain, disease  
 (stroke, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Embolism  
 (thromboembolism, treatment; preparation of heterocycl benzamides as  
 inhibitors of factor Xa and factor VIIa)  
 IT Blood coagulation  
 Cardiovascular system, disease  
 Fibrinolysis  
 Inflammation  
 Multiple organ failure  
 Neoplasm  
 (treatment; preparation of heterocycl benzamides as inhibitors of  
 factor Xa and factor VIIa)

IT Infection  
 (viral, treatment; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 9002-05-5, Factor xa 65312-43-8, Factor viia  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 438570-05-9P 438570-06-0P 438570-07-1P 438570-08-2P  
 438570-09-3P 438570-10-6P 438570-11-7P 438570-12-8P  
 438570-13-9P 438570-14-0P 438570-15-1P 438570-16-2P  
 438570-17-3P 438570-18-4P 438570-19-5P 438570-20-8P  
 438570-21-9P 438570-22-0P 438570-23-1P 438570-24-2P  
 438570-25-3P 438570-26-4P 438570-27-5P 438570-28-6P  
 438570-29-7P 438570-30-0P 438570-31-1P 438570-32-2P  
 438570-33-3P 438570-34-4P 438570-35-5P 438570-36-6P  
 438570-37-7P 438570-38-8P 438570-39-9P 438570-40-2P  
 438570-41-3P 438570-42-4P 438570-43-5P 438570-44-6P  
 438570-45-7P 438570-46-8P 438570-47-9P 438570-48-0P  
 438570-49-1P 438570-50-4P 438570-51-5P 438570-52-6P  
 438570-53-7P 438570-54-8P 438570-55-9P 438570-56-0P  
 438570-57-1P 438570-58-2P 438570-59-3P 438570-60-6P  
 438570-61-7P 438570-62-8P 438570-63-9P 438570-64-0P  
 438570-65-1P 438570-66-2P 438570-67-3P 438570-68-4P  
 438570-69-5P 438570-70-8P 438570-71-9P 438570-72-0P  
 438570-73-1P 438570-74-2P 438570-75-3P 438570-76-4P  
 438570-77-5P 438570-78-6P 438570-79-7P 438570-80-0P  
 438570-81-1P 438570-82-2P 438570-83-3P 438570-84-4P  
 438570-85-5P 438570-86-6P 438570-87-7P 438570-88-8P  
 438570-89-9P 438570-90-2P 438570-91-3P 438570-92-4P  
 438570-93-5P 438570-94-6P 438570-95-7P 438570-96-8P  
 438570-97-9P 438570-98-0P 438570-99-1P 438571-00-7P  
 438583-13-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclyl benzamides as inhibitors of factor Xa and factor VIIa)

IT 68-35-9 99-06-9, 3-Hydroxybenzoic acid, reactions 106-39-8,  
 4-Bromochlorobenzene 108-86-1, Bromobenzene, reactions 120-92-3,  
 Cyclopentanone 459-46-1, 1-(Bromomethyl)-4-fluorobenzene  
 1008-91-9 1072-98-6 1514-87-0, Methyl chlorodifluoroacetate  
 1538-75-6, Pivalic anhydride 1822-51-1 1916-08-1 2549-93-1,  
 1,4-Cyclohexanedimethanamine 2675-89-0, 2-Chloro-N,N-dimethylacetamide 2706-56-1, 2-Pyridin-2-ylethylamine 2766-74-7  
 3529-08-6, 3-Piperidin-1-ylpropylamine 3678-63-5,  
 4-Chloro-2-picoline 3943-89-3, Ethyl 3,4-dihydroxybenzoate  
 10394-38-4 13258-63-4, 4-Pyridineethanamine 13472-85-0,  
 5-Bromo-2-methoxypyridine 14348-38-0, 4-Bromo-3-hydroxybenzoic acid 16498-81-0, 2-Methoxynicotinic acid 17201-43-3,  
 4-(Bromomethyl)benzonitrile 19438-10-9, 3-Hydroxybenzoic acid methyl ester 19524-06-2, 4-Bromopyridine hydrochloride  
 27578-60-5, 2-Piperidin-1-ylethylamine 31462-56-3 39178-35-3  
 39890-45-4 55579-01-6 57260-71-6 62089-74-1 81156-68-5,  
 2-(2,4-Dichlorophenyl)ethanol 91323-34-1 144222-22-0, tert-Butyl 4-aminomethylpiperidine-1-carboxylate 149898-87-3 153863-92-4,  
 Furo[3,2-c]pyridine-2-methanamine 156972-83-7 166954-15-0

10/023933

323594-39-4 335439-70-8 335439-76-4 435321-22-5 438571-19-8  
438571-20-1 438571-21-2 438571-22-3 438571-23-4 438571-24-5  
438571-25-6 438571-26-7 438571-27-8 438583-12-1


RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and  
factor VIIa)

IT 58123-77-6P, 3-Hydroxy-4-iodobenzoic acid 83011-43-2P, Methyl  
3-hydroxy-4,5-dimethoxybenzoate 106291-80-9P 157942-12-6P  
382150-30-3P 435321-16-7P 438571-01-8P 438571-02-9P  
438571-03-0P 438571-04-1P 438571-05-2P 438571-06-3P  
438571-07-4P 438571-08-5P 438571-09-6P 438571-10-9P  
438571-11-0P 438571-12-1P 438571-13-2P 438571-14-3P  
438571-15-4P 438571-16-5P 438571-17-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent)  
(preparation of heterocyclyl benzamides as inhibitors of factor Xa and  
factor VIIa)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE  
IN THE RE FORMAT

FILE 'MARPATPREV' ENTERED AT 11:34:00 ON 19 MAY 2004

L9 STR



VAR G1=C/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:


10/023933

ECLEVEL IS LIM ON ALL NODES  
ALL RING(S) ARE ISOLATED

L12 0 SEA FILE=MARPATPREV SSS FUL L9 (MODIFIED ATTRIBUTES)

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

(FILE 'CASREACT' ENTERED AT 11:34:27 ON 19 MAY 2004)  
L3 STR



VAR G1=C/N  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:  
RSPEC I  
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE  
L14 0 SEA FILE=CASREACT SSS FUL L3 ( 0 REACTIONS)

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS  
SEARCH TIME: 00.00.01

(FILE 'DJSMD5, CHEMINFORMRX' ENTERED AT 11:35:21 ON 19 MAY 2004)  
L3 STR

10/023933



VAR G1=C/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

L15 0 SEA L3

FILE 'HOME' ENTERED AT 11:35:45 ON 19 MAY 2004